Significant Drug Launches in 2019: A Research Analysis and Insights on Pharmaceutical Industry

Table 1: Potential Launches to Watch, 2019
Table 2: Top Companies Investing in R&D, 2018
Table 3: Potential Drug Launches, 2018
Table 4: Key Clinical Trials of Ultomiris
Table 5: Common Symptoms of PNH
Table 6: Other Pipeline Drugs for PNH
Table 7: Key Development Milestones of Ultomiris
Table 8: Alexion Pharmaceuticals Inc.: Financial Performance, 2016-2018
Table 9: Alexion Pharmaceuticals Inc.: Product Portfolio
Table 10: Alexion Pharmaceuticals Inc.: Pipeline Molecules
Table 11: Alexion Pharmaceuticals, Inc.: Recent Acquisitions
Table 12: Clinical Evidence of Safety and Efficacy of Upadacitinib
Table 13: Epidemiological Forecast for Diagnosed Prevalent Cases of Rheumatoid Arthritis, by Region, Through 2022
Table 14: Common Symptoms of RA
Table 15: Unmet Needs of RA
Table 16: Current Treatment for RA
Table 17: Pipeline Molecules for RA
Table 18: Others Pipeline Drug for JAK Inhibitors
Table 19: AbbVie, Inc.: Financial Performance, 2016-2018
Table 20: AbbVie Inc.: Product Portfolio
Table 21: AbbVie Inc.: Pipeline Molecules
Table 22: AbbVie Inc.: Recent Acquisitions
Table 23: Classification of SMA
Table 24: Milestones in Discovery of SMA
Table 25: Pipeline Molecules, SMA
Table 26: Novartis AG: Financial Performance, 2016-2018
Table 27: Novartis AG: Product Portfolio, Oncology
Table 28: Novartis AG: Product Portfolio, Ophthalmology
Table 29: Novartis AG: Product Portfolio, Immunology Hepatology and Dermatology
Table 30: Novartis AG: Product Portfolio, Neuroscience
Table 31: Novartis AG: Product Portfolio, Respiratory
Table 32: Novartis AG: Product Portfolio, Pipeline Molecules
Table 33: Novartis AG: Recent Acquisitions
Table 34: Therapeutic Trials of Brolucizumab on Safety and Efficacy
Table 35: Projected Number of People with AMD, by Region, Through 2024
Table 36: AREDS Classification of AMD
Table 37: Pipeline Molecules for AMD
Table 38: Market Size of Lucentis and Eylea, Through 2022
Table 39: Incident and Prevalent Cases of MS, by Country, 2016
Table 40: Incident and Prevalent Cases of MS, by Region, 2016
Table 41: Currently Approved Disease Modifying Therapies for MS, Injectable Treatments
Table 42: Currently Approved Disease Modifying Therapies for MS, Oral Treatments
Table 43: Currently Approved Disease Modifying Therapies for MS, Intravenous Infusion Treatments
Table 44: Pipeline Molecules for Multiple Sclerosis Showing Promising Results
Table 45: Development Milestones of Risankizumab
Table 46: Currently Available Treatment for Psoriasis, Biologics
Table 47: Pipeline Molecules in Development for Psoriasis and Related Conditions: Phase III
Table 48: Pipeline Molecules in Development for Psoriasis and Related Conditions: Phase II
Table 49: Global Psoriasis Market, by Region/Country, Through 2022
Table 50: Pipeline Molecules: Beta Thalassemia
Table 51: Bluebird Bio Inc.: Financial Performance, 2016-2018
Table 52: Bluebird Bio Inc.: Pipeline Molecules as of 2019
Table 53: Currently Approved Disease Modifying Therapies for MS, Injectable Treatments
Table 54: Currently Approved Disease Modifying Therapies for MS, Oral Treatments
Table 55: Currently Approved Disease Modifying Therapies for MS, Intravenous Infusion Treatments
Table 56: Pipeline Molecules of Multiple Sclerosis Showing Promising Results
Table 57: Development Milestones of Ozanimod as of 2019
Table 58: Celgene Corp.: Revenue Details, 2016-2018
Table 59: Celgene Corp.: Marketed Products
Table 60: Celgene Corp.: Company Agreements
Table 61: Common Symptoms of Peanut Allergy
Table 62: Common Symptoms of Rheumatoid Arthritis
Table 63: Unmet Needs of Rheumatoid Arthritis
Table 64: Current Treatment for Rheumatoid Arthritis
Table 65: Pipeline Molecules for Rheumatoid Arthritis
Table 66: Gilead Sciences Inc.: Net Revenue, 2016-2018
Table 67: Gilead Science Inc.: Marketed Products
Table 68: Gilead Science Inc.: Pipeline Molecules
Table 69: Acronyms Used in This Report

Figure 1: Percentage Distribution of R&D Spending for Clinical Development of Novel Drugs, by Therapeutic Category, 2019
Figure 2: Market Share Analysis of Major Players in the Global Pharmaceutical Industry, 2018
Figure 3: Soliris: Net Product Revenues, 2014-2018
Figure 4: Spinraza: Market Size, 2016-2018
Figure 5: Novartis AG: Spending on Research and Development, by Division, 2017 and 2018
Figure 6: Brolucizumab: Mechanism of Action
Figure 7: Top Eight Food Items Triggering Allergy and Number of Children Affected, 2018
Figure 8: Percentage Distribution of Drug Launches, by Therapeutic Category, 2019